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The purpose of Grant # DE-FG03 98ER62674, Project # 55800112 was to
continue a previously funded effort and make a statistical comparison of the respective
toxicities of 22GRavs. 239Puin dogs. Special emphasis was on the induction of bone tumors
that result from the alpha-radiation emitted from either radionuclide.With the support
provided, we have completed the statistical analysis of 22GRaand have established a sound
basis for the analysis of the corresponding 239Pudata and for the comparison of these 2
nuclides.
The analysis of the Ra project is the cornerstone for a determination of the Pu toxicity, as
this will provide the link between animal experiments and existing human data.
Specifically:
Existing data obtained from the Ra project carried out at the University of Utah
between 1952 and 1987 were reviewed. They are summarized in Table 1. For the present
analysis , we selected nonparametric( 1,2,3) and parametric procedures (4,5,6). The event
time variable was either death from natural causes or death with bone tumor. It should be
emphasized that all dogs diagnosed with bone tumor were euthanized when humanitarian
reasons no longer justified keeping the animals alive. Throughout the project carried out
at the University of Utah, surgical removal of bone tumors, as for instance by amputation
of an affected limb, was not practiced, but soft tissue tumors were removed when
possible. An analysis of failures from soft tissue tumors, especially mammary tumors and
liver tumors, has been carried out and published previously (7-1 1). The Kaplan-Meier
(12) (KM) weighted fractional survivals and the corresponding cumulative hazards for
both modes of failure (death from all causes and from bone tumor) are shown in Figure 1.
The choice of a statistical model depends strongly on the statistical distribution of the
data. Figure 2 shows that plots of ( - in cumulative hazard) vs. in (t) approximate straight
lines with slopes >1. Coefficients of variation (r*) for the respective slopes and intercepts
all were in the range of 0.9 or greater, i. e. they are consistent with a Weibull distribution
of the failure time variable (1). As in previous analyses, regression models with
covariates were applied (4-6). The data can be applied to the accelerated failure time
model and the proportional hazards model. In these models, the covariates act
multiplicatively on the hazard function and additively on in (t) (6). The proportionality
condition was verified by showing that addition of a time dependent covariate produced a
coefficient that was not significantly different from zero.
Covariates or confounders were chosen from an array of variables that, potentially, could
modify survival. These covariates were used as linear and quadratic terms and in any
combination that did not result in overstratification. In addition, dose level groups
(GROUPS) which combine the effects of all confounders together were applied as
categorical variables with and without specific confounders.
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The accelerated failure time model is decribed by (6):
Y=cc+zp+crw
Where Yisthenatural logoffailure time, otisanintercept parameter, z~isa vectorof
covariates and their coefficients, cs is a scale parameter whose reciprocal y is the shape
parameter and W is a variable with specified distribution, in this case the Weibull
distribution. Thus, in addition to the estimation of the coefficients, the model requires the
calculation of the intercept and the scale parameter. The exponentiated coefficients are a
measure of the increase or decrease in hazard caused by a unit change in the covariate
value. For the proportional hazards model, the estimated coefficients must be multiplied
by the reciprocal of the scale parameter to yield a positive coefficient and an increment in
hazard. For the accelerated failure time model, the estimated coefficients are negative if
the covariate is associated with a decrease in life expectancy (or a decrease in survival
time).
For each set of covariates and for each dosage level, the parameters calculated allow the
construction of the needed survival and hazard curves and their comparison with the data
derived from the KM analysis (12). The curves are based on the following relationships:
exp <H
S(t)={ exp[-(kt)j} h(t )=L~(Lt~-’ ‘exp ~ pi
(Survival) (Hazard)
in which k is related to u in the model by: k = exp (-et) and the terms
So(t) = exp [- (M)y]
and ho(t )=ky(kt)y-’
are, respectively, the baseline survivals and baseline hazards, i. e. survivals or hazards in
the absence of specified confounders. In many cases, this corresponds to the controls.
With all parameters calculated by the regression, failure times for the construction of
survival curves were calculated as:
t = ~ ~-in (Surv.Fraction) L
k exp Zi pi
)Y
with
Median Surv. Time= ~ ln2 ~+
L ‘eXpZi pi
Hazard curves based on : h(t)= y L y *t ‘-1 for each dosage level were calculated by
performing the regression without specifying any covariates. These curves are shown in
Figure 3, which also lists the exponential (instead of the power function) parameters and
their coefficients of variation for each dosage level and for both modes of failure.
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Exponentiated regression coefficients were used to calculate from the accelerated failure
time model the change in life expectancy (life shortening) and using the proportional
hazards model, the relative hazards with respect to the controls or with respect to an
arbitrary reference. Selected survival curves and their underlying KM survivals are
shown in Figures 4 and 5. The curves, from left to right, represent the survivals of the
Ra40, Ra30, Ra20, Ra17, the collapsed dosage level groups and the Control group.
Figure 4 exhibits the curves calculated without inclusion of GROUP as a covariate. None
of the curves are in good agreement with the KM data, especially those with skeletal
dose or dosesquare as covariates. Figure 5 shows the effect of including the categorical
variable GROUP in the model. The fits are improved when compared to Figure 4. Curves
with Rate, Ratesquare and GROUP, those with Rate* GROUP and Ratesquare and with
GROUP alone gave the best fit. The dummy variables Rate* GROUP and Dose* GROUP
were introduced to overcome numerical problems that arose during the calculation.
Applying a Stepwise procedure (MPLR) (13) demonstrated that inclusion of additional
covariates or use of other covariate combinations did not improve the model.
Table 2 lists survivals calculated by the regression. Median survivals and life
expectancies can be compared with the original data shown in Table 1. Considering the
small size of the individual groups, the calculated data do fit the actual KM data quite
well. Also shown in Table 2 are the relative hazards with respect to a baseline hazard of
the controls.
It was planned to apply the same statistical techniques to the bone tumor (BT) population,
a cause specific failure, that were described above. Identical tests were performed to
justify the application of these procedures, i. e. determination of the statistical
distribution and verification of the proportional hazards condition. Cause specific failure
time analyses are generally carried out by taking only those specific events (in this case
bone tumors) as true failures and by censoring all other failures as loss to follow-up at the
time of their deaths. However, for the present analysis, the number of true failures and
their distribution within their respective dosage level subgroups required a somewhat
unconventional approach. As shown in Table 3, there were a total of31 bone tumors
among 98 dogs. Among 62 beagles in the collapsed group (05-17), there were only 4
dogs with a bone tumor, and their deaths were not uniformly distributed over the survival
curve. The estimated survivals of these four dogs fell between S(t)= 1 and S(t)=O.8. A
somewhat more favorable condition existed at dosage level =20 with 5 bone tumors
among 13 dogs, of which only one had a survival S(t)c 0.5. The remaining 22 BT deaths
occurred in the two highest dosage groups, level 30 and level 40. Listed are also the
actual average number of days to failure with BT and the KM weighted Median days to
failure, the average skeletal dose and dose rate. Considering that there was only one bone
tumor among 120 control beagles, the choice of a suitable reference group appeared
critical.
As for failures from all natural causes, KM-weighted fractional survivals were calculated
for the bone tumor population. The corresponding graph in Figure 1 shows that the small
number of tumors in the two low dosage levels together with the large number of dogs
remaining at risk after the last BT dog had died, produced a skewed survival pattern. An
identical picture is displayed by the respective cumulative hazards in the lower graph of
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Figure 1. The BT events simply never reached the median survival time for the complete
group. Nevertheless, as shown in Figure 2, plots of ln[-lnS(t)] vs. in (t) could be
described by straight lines of the form Y= a+bt and slopes >1, and the coefficients of
variation for the parameters were again close to 0.9. Inclusion in the string of tested
confounders of a time dependent covariate produced coefficients that were not
statistically different from zero. Therefore the proportionality conditions were not
violated and application of the accelerated failure time and the proportional hazards, or
relative risk, model were both justified.
Without specifying any covariates, survival hazards for each of the dosage level group of
the BT population also were calculated as for failures from all causes:
ho(t )=l@J)y-’
The curves and the exponential forms of the calculated equations are depicted in the
lower part of Figure 3. Coefficients of variation ~ were 0.9 or greater. The graph
emphasizes the sharp increase in hazard as the Ra dosage was increased to about 12
kBq/kg and higher.
Since neither the controls nor the low dosage level BT groups presented a suitable
baseline hazard, different reference populations had to be used. Figure 6 shows five
survival curves with different arbitrary baseline BT survivals. The top graph of Figure 6
shows the survivals obtained from using the Ra–injected dogs only and Ra 30 with 10/11
true failures as reference, i.e. Ra 30 = O and Ra 17 (05-17), Ra 20 and Ra 40 as covariates
with value 1. Curves are from left to right for level 40, level 30, level 20 and level 17.
The two center graphs include in the model the controls and the 4 Ra-injected groups. In
the left graph, the actual deaths of the controls (Status=Status) are compared with each
BT group (Status=BT). One has to consider that the natural lifespan of the controls
represents the limiting age and also a relative risk of one. In the right graph the controls
are again included in the model; however all but the single bone tumor were censored.
Thus, controls and BT dogs were both given a (Status=BT) designation. The baseline BT
survival calculated from
So(t) = exp [- (N)y]
is included as the reference. The lower graphs again include the controls as well as the
Ra-injected groups. In both cases the Status is BT. In addition to the GROUP covariates,
cumulative skeletal dose (DSK) or average dose rate (RATE) are included as continuous
variables, and the baseline survivals are given as a reference. All graphs correspond
reasonably well to the respective KM survivals. The best fit was obtained for curves
including average skeletal dose rate as a covariate while those with cumulative skeletal
dose fit the least well. This was observed also with deaths from natural causes The effect
of the low dosage level dogs remaining at risk after the last BT dog has died induced a
numerical shift to survivals that are beyond the natural life expectancy. Numerical
information on relative bone tumor risks and life expectancies for various models is
shown in Tables 4 and 5. A summary of relative bone tumor risks obtained with various
models used in the regression is found in Table 4. For convenience, the risk for the
collapsed Ra 17 level was set arbitrarily to 1, and the corresponding risks of the other
4
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groups were adjusted accordingly by adding or subtracting the calculated risk coefficients
of the Ra group to the coefficients of the other groups. Depending on the model, BT risks
defined as
Risk = exp ‘(ziPU-o)
vary widely, especially at the highest dosage level. Inclusion or omission of the master
control group in the model either with a survival Status=l or with BT=l did not appear to
lead to more consistent results. However, all models yield survival curves that conform
reasonably well to the KM data. Keeping in mind the goal of this analysis (that is a
comparison of the toxicities resulting from an internal burden of Ra or Pu, i. e. a toxicity
ratio), it is not necessary to choose a specific model. If the analysis of Pu that is in
progress at this time favors a certain model, that model can be used as long as the same
one or the same baseline is applied to the Ra data also.
Life Expectancies calculated using the same models as for the Relative Risks in Table 4
produced median times to death with bone tumor observed at the two highest dosage
levels that agree quite well with the Median KM survivals. The higher dosage levels are
characterized by a high incidence of bone tumors and a low proportion of censored dogs.
Thus, the events are uniformly distributed around the median of the whole population
(true events plus censored dogs). The statistical power of these data, therefore, is high.
For the low dosage groups, the number of censored dogs exceedes the number of events
and the events are not uniformly distributed throughout the survival curve. Bone tumors
fall mostly into the upper part of the curve where the fractional survival is high. The
tumors, however, cannot be isolated from the whole population because we must include
the nontumor dogs as long as these are at risk to develop a bone tumor. The model
assumes that BT is the only mode of death. It disregards the fact that other modes of
death will be in effect before BT can express itself. This leads to unrealistically long
(hypothetical) median survivals that far exceed the normal life span of the dogs. The
actual limiting life span then must be that of the control group. As pointed out above, this
does not prevent us from using these results in our later comparison with the Pu
population
The core of the Ra-Pu comparison now in progress will be the calculation of the
respective hazard and survival information and the comparison with the actual KM data.
Hazard ratios can then be calculated and relative risks of Ra /Pu for the two endpoints
(failure due to all natural causes and failure due to bone tumor), will be determined
5
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(Dosage
level)
lnj. kBq of
Ra /kg
(02)
0.237
(05)
0.707
(lo)
2.116
(17)
6.346
(20)
12.728
(30)
39.96
(40)
119.88
(Collapsed
D5-10 )
Controls
TABLE 1
BASIC DATA FOR CONTROLS AND BEAGLES INJECTED WITH 226Ra
(experimentally observed deaths from all natural causes)
# of
Beagles
/Group
10
25
23
14
13
11
12
48
132
# of
10
23
18
11
12
11
12
41
120
#of
Censore
o
2
5
3
1
0
0
7
12
KM -
Weighted
Av. Days
Post Inj.
3991
4434
4403
3984
3948
2211
1593
4428
4432
219
117
188
293
180
137
51
105
76
Kti -
Weighted
Median a
3611
4345
4065
3695
3775
2015
1553
4317
4575
Confidence
Intervalb
3448-4190
4180-4697
3860-4557
3254-4438
3440-4368
1897-2487
1471-1614
4141-4697
4234-4726
a If no exact Median was obtained, the interpolated Medians were used.
b Brookmeyer-Crowley 957. confidence intervals for median survival time.
c p-value for the significance of difference from controls.
P-
valuec
0.03
N.S.
N.S.
N.S.
<0.05
<0.001
<0.001
N.S.
Mantel
Statistic
4.65
0.92
0.02
1.58
9.5
163.3
194
Level 17 was no~ statistically different from level 20, but level 20 was different from level 30 and level 30
was different from level 40
. . .,
TABLE 2
SURVIVALS CALCULATED BY PARAMETRIC REGRESSION a
Median
Level Daysafter ~ a LifeExpectancyb * a Relative &o
Injection Risk b
Collapsed 4493 61 0.970 0.013 1.220 0.106
(05-10)
17 4186 161 0.922 0.022 1.719 0.297
20 3900 36 0.871 0.003 2.471 0.091
30 2282 47 0.480 0.024 127.8 42.08
40 1538 25 0.351 0.019 1180 191
a Averageof 3 analyseswith Group, Rate and Ratesquare as shown in Figure 5.
b Life Expectancy and Relative Risk of controls = 1.
. . -.
TABLE 3
BASIC DATA ON THE OCCURRENCE OF BONE TUMORS
\
Dosage
Parame- Level 05 10 17 05-17 20 30 40
ters
#of dogs [group 25 23 14 62 13 11 12
Dogs with osteosarcoma 1 2 1 4 5 10 12
Avg.days to failure with 4264 3753 2275 1593
BT
(actual)
Median days to failure
with BT
KM-weighted
Avg. skel. dose at
death –1 year(Gy)
Avg.dose rate to
death – 1 year
(mGy / day)
0.8
*O. 12
0.198
1.66 3.57
*0.77 *1.69
0.466 1.163
3644 4119 2099
1.744 8.95 19.1
al .98 ?4.03
0.478 2.50 10.2
1553
43.3
+15.1
37.9
-.
TABLE 4
SUMMARY OF RELATIVE BONE TUMOR RISKS CALCULATED FOR VARIOUS
MODELS
Median
Reference (Days) for Ra 17a Ra20a Ra30a Ra40a Model
Reference
Ra 30=0 2356 1 11.9 1199 21820 Ra Dogs Only
Ra 20=0 4500 1 11.8 1199
Ra 17=0 6367 1 11.8 1198
Contr. vs. Each 4497 1 10.8 721.2
Group
Rate,Ratesqu. 8436 1 10.1 3245
Groups b
Dsk,Dsksqu. 8478 1 8.84 2544
Groups b
Groups 8848 1 12.2 134’7
.
Groups 8803 1 12.2 1349
Each Group c 1 10.9 661.8
21807
21823
9191
46583
77188
26662
26582
14030
‘<
“
Controls and Ra
Dogs
“
“
Ra17= 02-17
Ra17= 05-17
Ra Dogs Only
others excluded
a These Risks were calculated by considering only dogs with bone tumor as failures, others were
censored. They assume that bone tumors are the only mode of death. Risks were arbitrarily based on the
hazards of the respective Reference curves. They were then normalized to a risk of 1 for the collapsed low
level group.
b Coefficients for Dose and Dosesquare were not significant; those for Rate and Ratesquare were
significant.
c Individual Groups were compared against each other.
TABLE 5
EFFECT OF Ra-DOSAGE ON LIFE EXPECTANCY CALCULATED FOR VARIOUS
MODELS
Median
Reference (Days) for Ra 17’ Ra20a Ra30‘ Ra40a Model
Reference
Ra 30=0 2356 6365 4498 2356 1568 Ra Dogs Only
Ra 20=0
Ra 17=0
Contr. vs. Each
Group
Rate, Ratesqu
Groups b
Dsk, Dsksqu.
Groups b
Groups
Groups
4500 6367 4499 2357 1569 “
6367 6368 4500 2357 1566 “
4497 6581 4513 2318 1555 Controls and Ra
Dogs
8463 6016 4491 2174 1554 “
8478 6433 4448 2394 1553 6’
8848 6336 4497 2366 1573 Ra17= 02-17
8803 6389 4498 2364 1573 Ral 7=05-17
a These Median Days were calculated by considering only dogs with bone tumor as failures, others
were censored. They assume that bone tumors are the only mode of death. In reality, days are limited to the
life span of the control dogs. For Level 30 and 40, life spans are very close to those calculated for all
deaths from natural causes
b Coefficients for Dose and Dosesquare were not significant, those for Rate and Ratesquare were
significant.
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